RESTYLANE® EYELIGHT w/Lidocaine

Where can I buy this product?

RESTYLANE® EYELIGHT™ w/ Lidocaine is available for purchase through Health Supplies Plus by licensed medical practitioners holding a valid medical license within the United States. First-time buyers can register an online account by providing required professional information, including US medical license verification and a valid shipping address. Account verification is typically completed within 2 business hours, after which you can purchase medical supplies at competitive wholesale pricing. Registered members may also be eligible for volume discounts and receive dedicated customer service support. We are committed to ensuring all products are sourced and sold exclusively to qualified US professionals.

Product Information

What is RESTYLANE® EYELIGHT™ w/ Lidocaine?

RESTYLANE® EYELIGHT™ w/ Lidocaine is a sterile, transparent gel of stabilized hyaluronic acid (HA) of non-animal origin, manufactured by Galderma. It is specifically formulated using Galderma’s NASHA® (Non-Animal Stabilized Hyaluronic Acid) technology and is FDA-approved for the improvement of infraorbital hollows (tear troughs) in adults over the age of 21.

The NASHA® technology in EYELIGHT™ is designed to produce a gel with low water-binding capacity, minimizing the risk of post-injection swelling common in the delicate tear trough area. This formulation typically contains 20mg/mL of stabilized hyaluronic acid and includes 0.3% lidocaine hydrochloride to enhance patient comfort during the injection procedure.

Storage: RESTYLANE® EYELIGHT™ w/ Lidocaine should be stored up to 25°C (77°F). Do not freeze. Protect from light.

Authenticity: Health Supplies Plus guarantees that all RESTYLANE® products are authentic, sourced through appropriate US channels, and handled according to manufacturer specifications.

Note: For professional use only. FDA-approved specifically for infraorbital hollows.

How does RESTYLANE® EYELIGHT™ w/ Lidocaine work?

RESTYLANE® EYELIGHT™ targets volume loss in the tear trough area, a primary cause of under-eye hollows and shadows. Utilizing NASHA® technology formulated for low hydrophiilicity, the stabilized HA gel adds volume directly beneath the skin in the infraorbital region upon precise injection.

By physically filling the hollow space, it lifts the tissue, smooths the transition between the lower eyelid and cheek, and reduces the shadowing effect caused by volume deficit. The specific properties of the NASHA® gel aim to provide structural support with minimal water attraction, leading to predictable results and reduced risk of edema in this sensitive anatomical zone.

Treatment results are visible immediately, although final results are best assessed after any initial swelling resolves. Clinical studies indicate that the effects of RESTYLANE® EYELIGHT™ can last up to 18 months, though individual patient results will vary. The integrated lidocaine significantly improves patient comfort during the procedure.

Indications for Use (US FDA Approved)

RESTYLANE® EYELIGHT™ w/ Lidocaine is indicated for patients over the age of 21 for:

• Improvement of infraorbital hollows (tear trough deformity) by volume augmentation.

This treatment requires advanced injector training, a thorough understanding of periorbital anatomy, careful patient selection (e.g., assessing skin quality, presence of fat pads, pigmentation vs. true hollows), and precise injection technique. Practitioners must consult the US Prescribing Information (or IFU) for full details and contraindications.

Primary Benefits

• Specifically FDA-approved for correcting infraorbital hollows (tear troughs).
• Utilizes NASHA® technology formulated for low water binding, minimizing swelling risk.
• Provides volume to reduce the appearance of under-eye hollows and shadows.
• Offers results lasting up to 18 months (clinically proven).
• Contains lidocaine for improved patient comfort in the sensitive under-eye area.
• Helps create a refreshed and less tired appearance.

Side Effects and Safety Information

Practitioners must consult the complete US Prescribing Information (or IFU) provided with the product for comprehensive details on indications, contraindications, warnings, precautions, and potential adverse events. Treatment of the infraorbital area is complex and requires advanced training and meticulous technique due to the thin skin and proximity to critical structures. It is essential to discuss all potential risks and side effects thoroughly with patients prior to treatment.

Common side effects observed in clinical trials are typically mild to moderate, temporary, and related to the injection site, including:

• Swelling
• Redness
• Tenderness or Pain
• Bruising
• Lumps/Bumps (palpable material)
• Itching

Severe Adverse Events and Specific Tear Trough Risks:
While generally safe when administered correctly by a trained professional, injections in the infraorbital area carry specific risks beyond those of general filler injections:

• Vascular Occlusion (VO): Accidental injection into infraorbital or angular vessels can obstruct blood flow, potentially leading to skin necrosis, scarring, or, in rare but devastating cases, retrograde embolism causing **vision impairment or blindness**. Thorough knowledge of vascular anatomy and immediate management protocols are absolutely critical.
• **Persistent Edema/Malar Edema:** Swelling that lasts longer than expected or involves the cheek area.
• **Tyndall Effect:** Bluish discoloration if the filler is placed too superficially under thin skin.
• Nodule or Granuloma Formation
• Inflammation or Infection
• Severe Allergic Reactions (anaphylaxis)
• Prolonged Pain or Sensory Disturbances
• Migration of filler
• Herpetic Eruptions

Any sign of vascular compromise, persistent swelling, visual changes, or suspected infection requires immediate medical evaluation and intervention.